We are analyzing https://link.springer.com/article/10.1007/s00262-017-2023-x.

Title:
LILRB receptor-mediated regulation of myeloid cell maturation and function | Cancer Immunology, Immunotherapy
Description:
The leukocyte immunoglobulin-like receptor (LILR) family comprises a set of paired immunomodulatory receptors expressed among human myeloid and lymphocyte cell populations. While six members of LILR subfamily A (LILRA) associate with membrane adaptors to signal via immunoreceptor tyrosine-based activating motifs (ITAM), LILR subfamily B (LILRB) members signal via multiple cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIM). Ligand specificity of some LILR family members has been studied in detail, but new perspective into the immunoregulatory aspects of this receptor family in human myeloid cells has been limited. LILRB receptors and the murine ortholog, paired immunoglobulin-like receptor B (PIRB), have been shown to negatively regulate maturation pathways in myeloid cells including mast cells, neutrophils, dendritic cells, as well as B cells. Our laboratory further demonstrated in mouse models that PIRB regulated functional development of myeloid-derived suppressor cell and the formation of a tumor-permissive microenvironment. Based on observations from the literature and our own studies, our laboratory is focusing on how LILRs modulate immune homeostasis of human myeloid cells and how these pathways may be targeted in disease states. Integrity of this pathway in tumor microenvironments, for example, permits a myeloid phenotype that suppresses antitumor adaptive immunity. This review presents the evidence supporting a role of LILRs as myeloid cell regulators and ongoing efforts to understand the functional immunology surrounding this family.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Business & Finance

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

The income method remains a mystery to us.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Link.springer.com has a secret sauce for making money, but we can't detect it yet.

Keywords {🔍}

pubmed, article, google, scholar, cas, receptor, cells, central, immunol, cell, human, receptors, immunoglobulinlike, inhibitory, leukocyte, lilrb, ilt, cancer, chen, myeloid, dendritic, iglike, zhang, transcript, pirb, paired, suppressor, activation, class, usa, research, expression, sci, blood, takai, family, liu, nat, signaling, med, pan, lilr, angiopoietinlike, suciufoca, mhc, binding, hlag, regulates, patients, privacy,

Topics {✒️}

ping-ying pan & shu-hsia chen fcgammari-mediated clathrin-dependent endocytosis month download article/chapter myeloid-derived suppressor cells myeloid-derived suppressor cell shu-hsia chen cd85/lir-1/ilt2 inhibitory receptor potential immune-related marker fcgammari-mediated monocyte activation fc receptor gamma-chain il-6–stat3 signaling pathway ilt/lir/mir clusters promote long-term survival hla-g-binding leukocyte immunoglobulin alternative hla-b27 structures lilrb receptor-mediated regulation small-cell lung cancer major histocompatibility complex angptl2/lilrb2 signaling promotes full article pdf inhibits bcr-induced activation article cancer immunology macrophage integrin signaling hematopoietic stem cells focussed research reviews activating mast cells pir-b-deficient mice myeloid cell maturation protein tyrosine phosphatases blood dendritic cells related subjects privacy choices/manage cookies human myeloid cells inhibitory receptor lilrb4 inhibits tcr signaling myeloid cell regulators negatively regulates neutrophil syk tyrosine kinase activating ilt receptor van nes jg dendritic cells involved itim-bearing ig transcript 3-fc modulates constitutive tyrosine phosphorylation inhibits human osteoclast receptor-mediated activation sloane de human dendritic cells natural killer cells lung cancer cells

Schema {🗺️}

WebPage:
      mainEntity:
         headline:LILRB receptor-mediated regulation of myeloid cell maturation and function
         description:The leukocyte immunoglobulin-like receptor (LILR) family comprises a set of paired immunomodulatory receptors expressed among human myeloid and lymphocyte cell populations. While six members of LILR subfamily A (LILRA) associate with membrane adaptors to signal via immunoreceptor tyrosine-based activating motifs (ITAM), LILR subfamily B (LILRB) members signal via multiple cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIM). Ligand specificity of some LILR family members has been studied in detail, but new perspective into the immunoregulatory aspects of this receptor family in human myeloid cells has been limited. LILRB receptors and the murine ortholog, paired immunoglobulin-like receptor B (PIRB), have been shown to negatively regulate maturation pathways in myeloid cells including mast cells, neutrophils, dendritic cells, as well as B cells. Our laboratory further demonstrated in mouse models that PIRB regulated functional development of myeloid-derived suppressor cell and the formation of a tumor-permissive microenvironment. Based on observations from the literature and our own studies, our laboratory is focusing on how LILRs modulate immune homeostasis of human myeloid cells and how these pathways may be targeted in disease states. Integrity of this pathway in tumor microenvironments, for example, permits a myeloid phenotype that suppresses antitumor adaptive immunity. This review presents the evidence supporting a role of LILRs as myeloid cell regulators and ongoing efforts to understand the functional immunology surrounding this family.
         datePublished:2017-06-21T00:00:00Z
         dateModified:2017-06-21T00:00:00Z
         pageStart:1079
         pageEnd:1087
         sameAs:https://doi.org/10.1007/s00262-017-2023-x
         keywords:
            LILRB
            LILRA
            ITIM
            Macrophage
            SHP
            Regulatory myeloid suppressor cells
            Oncology
            Immunology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-017-2023-x/MediaObjects/262_2017_2023_Fig1_HTML.gif
         isPartOf:
            name:Cancer Immunology, Immunotherapy
            issn:
               1432-0851
               0340-7004
            volumeNumber:66
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Berlin Heidelberg
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:William van der Touw
               affiliation:
                     name:Icahn School of Medicine at Mount Sinai
                     address:
                        name:Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Hui-Ming Chen
               affiliation:
                     name:Icahn School of Medicine at Mount Sinai
                     address:
                        name:Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA
                        type:PostalAddress
                     type:Organization
                     name:Houston Methodist Research institute
                     address:
                        name:Immunotherapy Research Center, Houston Methodist Research institute, Houston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ping-Ying Pan
               affiliation:
                     name:Icahn School of Medicine at Mount Sinai
                     address:
                        name:Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA
                        type:PostalAddress
                     type:Organization
                     name:Houston Methodist Research institute
                     address:
                        name:Immunotherapy Research Center, Houston Methodist Research institute, Houston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Shu-Hsia Chen
               affiliation:
                     name:Icahn School of Medicine at Mount Sinai
                     address:
                        name:Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA
                        type:PostalAddress
                     type:Organization
                     name:Houston Methodist Research institute
                     address:
                        name:Immunotherapy Research Center, Houston Methodist Research institute, Houston, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:LILRB receptor-mediated regulation of myeloid cell maturation and function
      description:The leukocyte immunoglobulin-like receptor (LILR) family comprises a set of paired immunomodulatory receptors expressed among human myeloid and lymphocyte cell populations. While six members of LILR subfamily A (LILRA) associate with membrane adaptors to signal via immunoreceptor tyrosine-based activating motifs (ITAM), LILR subfamily B (LILRB) members signal via multiple cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIM). Ligand specificity of some LILR family members has been studied in detail, but new perspective into the immunoregulatory aspects of this receptor family in human myeloid cells has been limited. LILRB receptors and the murine ortholog, paired immunoglobulin-like receptor B (PIRB), have been shown to negatively regulate maturation pathways in myeloid cells including mast cells, neutrophils, dendritic cells, as well as B cells. Our laboratory further demonstrated in mouse models that PIRB regulated functional development of myeloid-derived suppressor cell and the formation of a tumor-permissive microenvironment. Based on observations from the literature and our own studies, our laboratory is focusing on how LILRs modulate immune homeostasis of human myeloid cells and how these pathways may be targeted in disease states. Integrity of this pathway in tumor microenvironments, for example, permits a myeloid phenotype that suppresses antitumor adaptive immunity. This review presents the evidence supporting a role of LILRs as myeloid cell regulators and ongoing efforts to understand the functional immunology surrounding this family.
      datePublished:2017-06-21T00:00:00Z
      dateModified:2017-06-21T00:00:00Z
      pageStart:1079
      pageEnd:1087
      sameAs:https://doi.org/10.1007/s00262-017-2023-x
      keywords:
         LILRB
         LILRA
         ITIM
         Macrophage
         SHP
         Regulatory myeloid suppressor cells
         Oncology
         Immunology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-017-2023-x/MediaObjects/262_2017_2023_Fig1_HTML.gif
      isPartOf:
         name:Cancer Immunology, Immunotherapy
         issn:
            1432-0851
            0340-7004
         volumeNumber:66
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Berlin Heidelberg
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:William van der Touw
            affiliation:
                  name:Icahn School of Medicine at Mount Sinai
                  address:
                     name:Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Hui-Ming Chen
            affiliation:
                  name:Icahn School of Medicine at Mount Sinai
                  address:
                     name:Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA
                     type:PostalAddress
                  type:Organization
                  name:Houston Methodist Research institute
                  address:
                     name:Immunotherapy Research Center, Houston Methodist Research institute, Houston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ping-Ying Pan
            affiliation:
                  name:Icahn School of Medicine at Mount Sinai
                  address:
                     name:Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA
                     type:PostalAddress
                  type:Organization
                  name:Houston Methodist Research institute
                  address:
                     name:Immunotherapy Research Center, Houston Methodist Research institute, Houston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Shu-Hsia Chen
            affiliation:
                  name:Icahn School of Medicine at Mount Sinai
                  address:
                     name:Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA
                     type:PostalAddress
                  type:Organization
                  name:Houston Methodist Research institute
                  address:
                     name:Immunotherapy Research Center, Houston Methodist Research institute, Houston, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Immunology, Immunotherapy
      issn:
         1432-0851
         0340-7004
      volumeNumber:66
Organization:
      name:Springer Berlin Heidelberg
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Icahn School of Medicine at Mount Sinai
      address:
         name:Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA
         type:PostalAddress
      name:Icahn School of Medicine at Mount Sinai
      address:
         name:Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA
         type:PostalAddress
      name:Houston Methodist Research institute
      address:
         name:Immunotherapy Research Center, Houston Methodist Research institute, Houston, USA
         type:PostalAddress
      name:Icahn School of Medicine at Mount Sinai
      address:
         name:Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA
         type:PostalAddress
      name:Houston Methodist Research institute
      address:
         name:Immunotherapy Research Center, Houston Methodist Research institute, Houston, USA
         type:PostalAddress
      name:Icahn School of Medicine at Mount Sinai
      address:
         name:Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA
         type:PostalAddress
      name:Houston Methodist Research institute
      address:
         name:Immunotherapy Research Center, Houston Methodist Research institute, Houston, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:William van der Touw
      affiliation:
            name:Icahn School of Medicine at Mount Sinai
            address:
               name:Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA
               type:PostalAddress
            type:Organization
      name:Hui-Ming Chen
      affiliation:
            name:Icahn School of Medicine at Mount Sinai
            address:
               name:Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA
               type:PostalAddress
            type:Organization
            name:Houston Methodist Research institute
            address:
               name:Immunotherapy Research Center, Houston Methodist Research institute, Houston, USA
               type:PostalAddress
            type:Organization
      name:Ping-Ying Pan
      affiliation:
            name:Icahn School of Medicine at Mount Sinai
            address:
               name:Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA
               type:PostalAddress
            type:Organization
            name:Houston Methodist Research institute
            address:
               name:Immunotherapy Research Center, Houston Methodist Research institute, Houston, USA
               type:PostalAddress
            type:Organization
      name:Shu-Hsia Chen
      affiliation:
            name:Icahn School of Medicine at Mount Sinai
            address:
               name:Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA
               type:PostalAddress
            type:Organization
            name:Houston Methodist Research institute
            address:
               name:Immunotherapy Research Center, Houston Methodist Research institute, Houston, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA
      name:Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA
      name:Immunotherapy Research Center, Houston Methodist Research institute, Houston, USA
      name:Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA
      name:Immunotherapy Research Center, Houston Methodist Research institute, Houston, USA
      name:Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA
      name:Immunotherapy Research Center, Houston Methodist Research institute, Houston, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(379)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.67s.

LINK . SPRINGER . COM {}